National University of Singapore researchers identify breast cancer target

Researchers at the National University of Singapore (NUS) have identified a regulatory mechanism known as the ‘DP103 master switch’ that drives growth, spread, and resistance in triple-negative breast cancer.

In laboratory and organoid models, the targeted drug RX-5902 (Supinoxin) was shown to deactivate DP103-related processes within the Wnt signaling pathway. This intervention resulted in a 40 to 60 percent reduction in cancer stem cell viability and, in some instances, a reduction in tumor growth of approximately 50 percent. The study also suggests that DP103 could serve as a diagnostic biomarker to identify patients most likely to benefit from this targeted approach.